DexCom (DXCM) Projected to Post Earnings on Thursday

Key Points

• DexCom is expected to release its Q3 2025 earnings on October 30, with analysts forecasting earnings of $0.57 per share and revenue of $1.1784 billion.
• In the previous quarter, DexCom reported earnings of $0.48 per share on revenue of $1.16 billion, surpassing consensus estimates and demonstrating a year-over-year revenue growth of 15.2%.
• Wall Street analysts maintain a positive outlook on DexCom, with a consensus price target of $96.40 and the stock receiving various buy ratings from analysts like Stifel Nicolaus and Morgan Stanley.

DexCom (NASDAQ:DXCM - Get Free Report) is expected to be releasing its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect DexCom to post earnings of $0.57 per share and revenue of $1.1784 billion for the quarter. DexCom has set its FY 2025 guidance at EPS.Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.43 EPS. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.70 on Thursday. The company's 50-day moving average is $72.76 and its 200 day moving average is $77.65. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a market capitalization of $27.73 billion, a P/E ratio of 49.10, a price-to-earnings-growth ratio of 1.46 and a beta of 1.47. DexCom has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on DXCM shares. Stifel Nicolaus started coverage on shares of DexCom in a report on Tuesday. They issued a "buy" rating and a $85.00 price target on the stock. Barclays increased their target price on shares of DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 10th. Morgan Stanley increased their target price on shares of DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Truist Financial cut their target price on shares of DexCom from $102.00 to $94.00 and set a "buy" rating for the company in a research report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $96.40.

Insider Activity

In related news, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,849 shares of company stock valued at $564,733. Corporate insiders own 0.32% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DXCM. Integrated Wealth Concepts LLC boosted its stake in shares of DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock worth $227,000 after acquiring an additional 196 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company's stock worth $1,681,000 after acquiring an additional 258 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company's stock worth $577,000 after acquiring an additional 436 shares during the last quarter. Banque Transatlantique SA boosted its stake in shares of DexCom by 71.2% in the second quarter. Banque Transatlantique SA now owns 1,500 shares of the medical device company's stock worth $131,000 after acquiring an additional 624 shares during the last quarter. Finally, Vident Advisory LLC boosted its stake in DexCom by 8.1% during the second quarter. Vident Advisory LLC now owns 8,381 shares of the medical device company's stock worth $732,000 after buying an additional 626 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.